版本:
中国

BRIEF-Aldeyra Therapeutics receives orphan drug designation from FDA

April 20 Aldeyra Therapeutics Inc:

* Aldeyra Therapeutics Inc receives orphan drug designation from the U.S. Food And Drug Administration for ADX-102 in sjögren-larsson syndrome

* Aldeyra Therapeutics Inc- FDA granted Aldeyra's novel compound ADX-102 orphan drug designation for treatment of congenital ichthyosis

* Aldeyra Therapeutics Inc- pivotal phase 3 study is expected to begin later this year Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐